BioNTech expands partnership with UK govt, pledging £1 billion investment

20 May 2025

German vaccine pioneer BioNTech (Nasdaq: BNTX) today revealed that its UK subsidiary has signed a grant agreement with the UK government to broaden the company’s R&D activities for innovative medicines in the UK.

As part of the agreement, BioNTech is committed to investing up to £1 billion ($1.33 billion) over the next 10 years. The company said its efforts will be supported by a grant of up to £129 million for a period of 10 years by the UK government, which marks one of the largest grants of its kind in UK history for a pharmaceutical company. The grant is part of the UK government’s mission to enhance its life sciences sector and support innovative companies with the aim to unlock progress in medical science, noted BioNTech .

This will see BioNTech create two new R&D hubs, the first to be based in Cambridge, as well as an AI hub to be based at BioNTech’s planned UK headquarters in London, according to the Department for Science, Innovation & Technology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK